Breaking Finance News

Cancer Genetics Inc (NASDAQ:CGIX) target price raised to $2.00, reported today by Zacks Investment Research

Cancer Genetics Inc (NASDAQ:CGIX) had its price target upped to $2.00 by Zacks Investment Research in a report released 10/11/2016. The bumped up target suggests a possible upside of 0.10% from the company's previous closing price.

Previously on 9/27/2016, HC Wainwright reported on Cancer Genetics Inc (NASDAQ:CGIX) increased the target price from $0.00 to $6.00. At the time, this indicated a possible upside of 2.41%.

Just yesterday Cancer Genetics Inc (NASDAQ:CGIX) traded -2.92% lower at $1.81. Cancer Genetics Inc’s 50-day moving average is $1.89 and its 200-day moving average is $2.17. The last closing price is down -23.67% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 118,949 shares of CGIX traded hands, up from an average trading volume of 112,372

Recent Performance Chart

Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics Inc has 52 week low of $1.60 and a 52 week high of $8.00 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokers have issued a research note on the company. The average stock price target is $8.42 with 2 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.